基于个人数字助理的药物信息来源：改善用药安全的潜力。

Personal digital assistant-based drug information sources: potential to improve medication safety.

作者信息

Galt Kimberly A, Rule Ann M, Houghton Bruce, Young Daniel O, Remington Gina

机构信息

Department of Pharmacy Practice, School of Pharmacy and Health Professions, Creighton University, 2500 California Plaza, Omaha, Nebraska 68178, USA.

出版信息

J Med Libr Assoc. 2005 Apr;93(2):229-36.

PMID:15858626

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC1082940/

Abstract

OBJECTIVES

This study compared the potential for personal digital assistant (PDA)-based drug information sources to minimize potential medication errors dependent on accurate and complete drug information at the point of care.

METHODS

A quality and safety framework for drug information resources was developed to evaluate 11 PDA-based drug information sources. Three drug information sources met the criteria of the framework: Eprocrates Rx Pro, Lexi-Drugs, and mobileMICROMEDEX. Medication error types related to drug information at the point of care were then determined. Forty-seven questions were developed to test the potential of the sources to prevent these error types. Pharmacists and physician experts from Creighton University created these questions based on the most common types of questions asked by primary care providers. Three physicians evaluated the drug information sources, rating the source for each question: 1=no information available, 2=some information available, or 3 = adequate amount of information available.

RESULTS

The mean ratings for the drug information sources were: 2.0 (Eprocrates Rx Pro), 2.5 (Lexi-Drugs), and 2.03 (mobileMICROMEDEX). Lexi-Drugs was significantly better (mobileMICROMEDEX t test; P=0.05; Eprocrates Rx Pro t test; P=0.01).

CONCLUSION

Lexi-Drugs was found to be the most specific and complete PDA resource available to optimize medication safety by reducing potential errors associated with drug information. No resource was sufficient to address the patient safety information needs for all cases.

摘要

目的

本研究比较了基于个人数字助理（PDA）的药物信息来源在依赖准确完整的即时护理药物信息以尽量减少潜在用药错误方面的潜力。

方法

制定了一个药物信息资源的质量与安全框架，以评估11种基于PDA的药物信息来源。三种药物信息来源符合该框架的标准：Eprocrates Rx Pro、Lexi-Drugs和mobileMICROMEDEX。然后确定了与即时护理时药物信息相关的用药错误类型。编制了47个问题，以测试这些信息来源预防这些错误类型的潜力。克里顿大学的药剂师和医生专家根据初级护理提供者最常提出的问题类型创建了这些问题。三名医生对药物信息来源进行评估，对每个问题的信息来源进行评分：1=无可用信息，2=有一些可用信息，或3=有足够的可用信息。

结果

药物信息来源的平均评分为：2.0（Eprocrates Rx Pro）、2.5（Lexi-Drugs）和2.03（mobileMICROMEDEX）。Lexi-Drugs明显更好（与mobileMICROMEDEX的t检验；P=0.05；与Eprocrates Rx Pro的t检验；P=0.01）。